Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

8.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K
  1. Home
  3. Systematic Identification Of Cancer-type-specific Drugs Based On Essential Genes And Validations In Lung Adenocarcinoma.
  1. Home
  3. Systematic Identification Of Cancer-type-specific Drugs Based On Essential Genes And Validations In Lung Adenocarcinoma.

Related Experiment Video

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Systematic identification of cancer-type-specific drugs based on essential genes and validations in lung

Xiang Lian1,2, Xia Kuang1, Dong-Dong Zhang1

  • 1Department of Respiratory and Critical Care Medicine, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, 185 Donghu Road, Wuchang District, Wuhan 430071, China.

Briefings in Bioinformatics
|June 8, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Researchers identified cancer-type-specific essential genes and drugs, showing lower toxicity compared to pan-cancer targets. This discovery offers new avenues for targeted cancer therapy with improved biocompatibility.

Keywords:
EssentialitySpecificityScorecancer-type-specific drugscell inhibition rateessential geneslung adenocarcinoma

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

Related Experiment Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

Area of Science:

  • Oncology
  • Pharmacology
  • Bioinformatics

Background:

  • Targeting essential genes is crucial for cancer therapy, but systematic investigations are lacking.
  • Existing drugs targeting essential genes may exhibit broad toxicity, necessitating more specific approaches.

Purpose of the Study:

  • To develop a strategy for identifying cancer-type-specific essential gene targets and associated drugs.
  • To evaluate the potential for reduced toxicity of drugs targeting cancer-specific essential genes compared to pan-cancer targets.

Main Methods:

  • A scoring function (EssentialitySpecificityScore) was developed to rank essential genes across 19 cancer types.
  • Cancer-type-specific targets and drugs were identified by integrating gene essentiality data with drug interaction databases and market status.
  • Experimental validation was performed on selected drugs in lung adenocarcinoma cell lines.

    • Main Results:

    • 1151 cancer-type-specific essential genes and 370 drugs targeting 100 of these genes were identified.
    • Drugs associated with cancer-type-specific targets were found to apply to fewer cancer types (<10).
    • Seven novel drugs showed significantly lower inhibition rates in normal cell lines compared to cancer cell lines (P ≤ 0.0001).

    Conclusions:

    • The developed scoring strategy effectively identifies cancer-type-specific targets and drugs, supporting the hypothesis of reduced toxicity.
    • The Essential Gene Knowledge Graph (EGKG) provides a computational framework for discovering targeted cancer therapies.
    • Combining drugs with orthogonal essentiality may enhance anticancer efficacy while preserving biocompatibility.